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Abstract
Introduction: Primary hepatic lymphoma is an unusual form of non-Hodgkin's lymphoma that
usually presents with constitutional symptoms, hepatomegaly and signs of cholestatic jaundice.
Diffuse hepatic infiltration is uncommon and presentation with acute hepatic failure even more
rare. The presence of markedly elevated ferritin levels can complicate the evaluation process and
suggest alternative diagnoses.
We present the case of a middle-aged woman exhibiting pancytopenia, hyperferritinemia and
rapidly deteriorating to develop acute hepatic failure. Her initial clinical picture led to a working
diagnosis of adult onset Still's disease with probable hemophagocytic syndrome before her
worsening liver function necessitated a percutaneous liver biopsy and establishment of the final
diagnosis of primary hepatic lymphoma.
Conclusion: Primary hepatic lymphoma is an uncommon malignancy and its manifestation as
progressive hepatitis or acute fulminant hepatic failure can be difficult to diagnose. The presence of
constitutional symptoms, pancytopenia and high ferritin levels can complicate the evaluation
process. A liver biopsy early in the course of liver dysfunction may establish the diagnosis without
a higher risk of bleeding complications seen once liver failure sets in.
Introduction
Primary Hepatic Lymphoma (PHL) is a rare variant of
non-Hodgkin's lymphoma with an incidence of < 1%. The
presence of diffuse hepatic involvement is uncommon
and therefore presentation as hepatocellular jaundice or
acute fulminant hepatic failure is rare.
We present a case where persistent fever, non-specific
symptoms, pancytopenia and strikingly high levels of
serum ferritin preceded the presentation of acute liver fail-
ure. Due to these findings, alternative diagnoses were
entertained including hemophagocytic syndrome in asso-
ciation with adult onset Still's disease (AOSD).
Case presentation
A 53-year-old Caucasian woman was transferred to our
facility for 3 weeks of intermittent fevers, chills, weight
loss, myalgias and arthralgias. She had mild epigastric dis-
comfort with nausea and vomiting. Dalteparin and warfa-
rin were started for a recently diagnosed pulmonary
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embolism. Her past history was remarkable for diabetes
mellitus type 2, hypertension and villous adenoma of the
colon. Subsequent colonoscopies were normal. Except for
mild epigastric tenderness, her physical examination find-
ings were normal. White blood cell (WBC) count was 4.5
K/μl, hemoglobin 10 g/dl, hematocrit 28.6% and platelets
had fallen to 95 K/μl from a baseline of 129 K/μl. Aspar-
tate aminotransferase (AST) was 67 U/liter and albumin
2.9 g/liter. Repeat imaging did not show a pulmonary
embolism but her spleen was enlarged (16.5 cm) with a
focal infarct. Argatroban, originally started for possible
heparin induced thrombocytopenia, was discontinued
when venous Dopplers, Ventilation-perfusion scan and
heparin antibodies were normal. Transesophageal
echocardiogram and all cultures were negative.
She continued to have fever up to 39.5°C. Lactate dehy-
drogenase (LDH) was 2075 U/liter and serum ferritin was
87,207 ng/ml. Transferrin saturation and B2-microglobu-
lin levels were normal. Antinuclear antibody (ANA) titer
was 1:40 and rheumatoid factor was negative. As her pan-
cytopenia deteriorated (WBC 3.9 K/μl, hemoglobin 8.8 g/
dl, platelets 44 K/μl), she was started on steroids for a pos-
sible diagnosis of adult onset Still's disease (AOSD) with
hemophagocytic syndrome. Bone marrow biopsy was
done and was normocellular with trilineage hematopoie-
sis without any hemophagocytosis.
After an initial improvement with steroids, liver function
rapidly declined (Table 1). Hepatitis A, B, C, EBV, CMV,
HIV as well as antismooth muscle and antimitochondrial
serologies were negative. Abdominal ultrasound did not
show any splenic, portal or hepatic vein thrombosis. Liver
biopsy was delayed for almost a week because of the
patient's persistent coagulopathy and arrangements were
being made to transfer her to a liver transplant center. A
percutaneous computed tomography (CT) guided liver
biopsy was performed. Her clinical course was compli-
cated by intra-abdominal hemorrhage (Figure 1) with
shock, respiratory failure, hepatic encephalopathy, lactic
acidosis and acute renal failure requiring temporary dial-
ysis. Biopsy revealed diffuse large B cell lymphoma (Fig-
ure 2).
Chemotherapy was started immediately. The patient
received a total of 6 cycles of chemotherapy; each cycle
was given every 21 days. Initially she received 2 cycles of
cyclophosphamide (1.5 g/m2) and rituximab and this
was because vincristine and adriamycin were contraindi-
cated due to her multi-organ failure. Though she showed
improvement, the chemotherapeutic regimen was not felt
to be adequate. She was then administered 2 cycles of R-
DHAP (cytarabine and cisplatin salvage regimen mostly
used for relapsed or refractory lymphoma). As her organ
function recovered, she received another 2 cycles of R-
CHOP (rituximab, cyclophosphamide, adriamycin, vinc-
ristine and prednisone).
A year into the diagnosis, she is in remission. CT scan does
not show any liver or spleen enlargement and a recent
positron emission tomography (PET) scan was also nega-
tive for lymphoma. Her blood counts, including liver
enzymes and creatinine, have normalized (WBC 5 K/μl,
platelets 161 K/μl, hemoglobin 13 g/dl). With the initia-
tion of chemotherapy, the patient's ferritin levels also rap-
idly declined. Her most recent ferritin level is 449 ng/ml
(range 13–150 ng/ml).
Table 1: Liver function tests
Hospital day
15 6 9 *1 11 51 71 8 1 9
TBil 0.6 0.9 1.2 2.3 1.4 1.6 3.4 3.8 5.1
DBil 0.2 0.4 0.3 1.6 0.9 0.9 2.1 2.8 3.8
AST 67 265 326 771 467 384 812 1585 1868
ALT 28 80 83 234 217 209 435 522 538
ALP 57 214 204 307 252 247 416 386 364
Albumin 2.9 3.1 2.6 2.7 2.5 2.6 2.4 2.6 2.6
PT 16.6 17.6 17.2 20.6 20.0 20.9
INR 1.5 1.7 1.7 2.3 2.2 2.4
TBil, total bilirubin (0.3–1.3.mg/dl); DBil, direct bilirubin (0.0–0.2 mg/
dl); AST, aspartate aminotransferase (8–46 U/liter); ALT, alanine 
aminotransferase (8–50 U/liter); ALP, alkaline phosphatase (25–125 
U/liter); PT, prothrombin time (12–14.secs); INR, International 
Normalized Ratio. *Addition of steroids.
Computed tomography scan of the abdomen without con- trast after the liver biopsy showed acute hemorrhage  (arrows) Figure 1
Computed tomography scan of the abdomen without con-
trast after the liver biopsy showed acute hemorrhage 
(arrows). The unenhanced liver is normal in size and attenua-
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Discussion
PHL is defined as lymphoma either confined to the liver
or with major liver involvement [1]. Median survival is 8
to 16 months and complete remission is low (< 20%). It
is important to recognize that in rare circumstances, it can
present with fulminant hepatic failure (FHF) and because
of the ambiguous features and rapid progression, most
cases are diagnosed on autopsy with an average survival of
10.7 days from diagnosis [2].
It is twice as common in men and the usual age at presen-
tation is 50 years. Exact etiology is unknown although
viruses such as hepatitis B, C and Epstein-Barr have been
implicated. Signs and symptoms can mimic a variety of
infectious and inflammatory disorders delaying the diag-
nosis. A preliminary diagnosis of AOSD was made in this
patient because of weeks of unexplained fever, hyperfer-
ritinemia, hepatitis, splenomegaly and a possible reactive
hemophagocytic syndrome [3,4]. AOSD is however a
diagnosis of exclusion. There have been reports of FHF
with AOSD especially with concomitant use of acetami-
nophen and ibuprofen, and therapy and treatment with
steroids can prevent liver transplantation [5]. For our
patient, addition of steroids temporarily masked the clin-
ical picture.
Ferritin is an acute phase reactant that can be elevated in a
variety of clinical conditions including liver diseases
(hemochromatosis), HIV, sepsis, malignancies including
leukemias and lymphomas, and hemophagocytic syn-
drome. In healthy patients, 50% to 80% of ferritin is gly-
cosylated, a process that provides a shield against the
proteolytic enzymes. In inflammatory diseases, there is
saturation of glycosylation mechanisms causing the glyc-
osylated fraction to drop to 20% to 50%. This occurrence
is particularly common in AOSD. Hence, combination of
fivefold and greater elevation of serum ferritin and a glyc-
osylated fraction of less than 20% has a sensitivity of 43%
but a specificity of 93% for a diagnosis of AOSD [6]. A gly-
cosylated ferritin level was not measured in our patient.
Since very high ferritin levels are frequently associated
with AOSD and hemophagocytic syndrome (HPS), it can
be a red herring.
As for PHL, the most frequent pathology is diffuse large B
cell followed by small lymphocytic, T cell, follicular and
marginal B cell lymphoma. Fever, anorexia and upper
quadrant pain are some of the symptoms. Though our
patient had no evidence of hepatomegaly on serial imag-
ing, liver enlargement is present in almost 80% of patients
and solitary or multiple discrete masses are commonly
found on computerized axial tomography (CAT) scan,
ultrasound or MRI. Diffuse infiltration is rare and more
common in the Chinese population [7]. Blood counts are
initially normal and pancytopenia should alert the clini-
cian to consider hemophagocytosis. More frequently asso-
ciated with T cell lymphomas, HPS has also been
described in B cell lymphomas [8]. Hemophagocytosis in
the biopsy (bone marrow, lymph nodes, liver or spleen) is
a prerequisite for diagnosis. Liver enzymes, including
LDH, are elevated in most cases of PHL and hypercal-
cemia may be present. Alfa fetoprotein and carcinoembry-
onic antigen markers are normal in all patients [9].
Liver biopsy remains the most valuable tool for diagnosis
of PHL. If a discrete mass is not visible on imaging for per-
cutaneous liver biopsy (PLB), the transjugular approach
may be reasonable. A recent review indicates that transjug-
ular liver biopsy can be used to obtain adequate tissue
samples and major complications and mortality rates are
similar to PLB [10]. Our patient had significant hemor-
rhage after the PLB, despite correction of the prothrombin
time to less than 15 seconds.
According to the Ann Arbor staging system, involvement
of the bone marrow, lung and liver constitute Stage IV dis-
ease. Our patient was classified as Stage IV, because of dif-
fuse liver involvement, rather than the traditional Stage IE
classification by Caccamo and colleagues [11]. In her sta-
tus, she would be expected to have a remission rate of just
over 50% and a 5-year survival rate of around 25%.
Chemotherapy is the main treatment modality although
surgery and radiotherapy have also been used. Standard
CHOP chemotherapy can be challenging with severe
hepatic dysfunction, and substantial dose reduction may
be required. It is important to recognize and identify the
causes of acute liver failure that require specific treatment,
Liver: Atypical large lymphoid infiltrates with distortion of  hepatic parenchyma Figure 2
Liver: Atypical large lymphoid infiltrates with distortion of 
hepatic parenchyma. These cells were CD20+ confirming the 
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such as lymphoma, Budd-Chiari syndrome, or ischemic
hepatitis [12]. While there have been a few cases of suc-
cessful liver transplantation in PHL [13], the role is con-
troversial. Liver histology is not routinely recommended
in FHF [14]. However, in certain selective cases, timely rec-
ognition by liver biopsy can decrease the need for referral
to a transplant center since an important variable for pre-
dicting the need of transplantation is the principal cause.
Conclusion
PHL can manifest as progressive hepatitis and acute
hepatic failure. The presence of constitutional symptoms,
hematological abnormalities and altered acute phase reac-
tants can complicate diagnostic evaluation.
If the clinical picture is suspicious for PHL, a liver biopsy
should be attempted as soon as there is evidence of hepa-
titis because rapid progression can cause FHF and refrac-
tory coagulopathy with bleeding complications.
Furthermore, early detection and timely initiation of com-
bination chemotherapy can improve survival [15].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
FSH completed most of the manuscript after evaluation of
the case, compilation of the data and literature review.
RES reviewed the manuscript and contributed to the liter-
ature review regarding hepatic failure and hepatic lym-
phoma. SSK contributed to the interpretation of the
histopathological data, the oncologic aspect of hepatic
lymphoma and its chemotherapy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
References
1. Salmon JS, Thompson MA, Arildsen RC, Greer JP: Non-Hodgkin's
lymphoma involving the liver: Clinical and therapeutic con-
siderations.  Clin Lymphoma Myeloma 2006, 6(4):273-280.
2. Lettieri CJ, Berg BW: Clinical features of non-Hodgkin's lym-
phoma presenting with acute liver failure: a report of five
cases and review of the published experience.  Am J Gastroen-
terol 2003, 98:1641-1646.
3. Coffernils M, Soupart A, Pradier O: Hyperferritinemia in adult
onset Still's disease and the hemophagocytic syndrome.  J
Rheumatol 1992, 19(9):1425.
4. Masson C, Le Loet X, Liote F, Dubost JJ, Boissier MC, Perroux-
Goumy L: Comparative study of 6 types of criteria in adult
Still's disease.  J Rheumatol 1996, 23(3):495-497.
5. Linde B, Oelzner P, Katenkamp K, Hein G, Wolf G: Fulminant liver
failure in a 39 year old female with leukocytosis, unclear
fever and arthralgic pain.  Med Klin (Munich) 2007,
102(10):846-851.
6. Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P: Diagnostic value
of ferritin and glycosylated ferritin in adult onset still's dis-
ease.  J Rheumatol 2001, 28(2):322-329.
7. Lei KIK, Chow JHS, Johnson PJ: Aggressive primary hepatic lym-
phoma in Chinese patients, presentation, pathologic fea-
tures and outcome.  Cancer 1995, 76:1336-1343.
8. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K: Lymphoma
associated hemophagocytic syndrome: clinicopathological
characteristics.  Ann Hematol 2000, 79(7):378-388.
9. Agmon-Levin N, Berger I, Shtalrid M, Schlanger H: Primary hepatic
lymphoma: a case report and review of literature.  Age Ageing
2004, 33:637-640.
10. Kalambokis G, Manousou P, Vibhakorn S, Marelli L: Transjugular
liver biopsy-indications, quality of specimens and complica-
tions – A systematic review.  J Hepatol 2007, 47:284-294.
11. Caccamo D, Perez NK, Marchevsky A: Primary lymphoma of the
liver in the acquired immunodeficiency syndrome.  Arch Pathol
Lab Med 1986, 110:553-555.
12. Williams R: Acute liver failure – practical management.  Acta
Gastroenterol Belg 2007, 70(2):210-213.
13. Cameron AM, Truty J, Truell J, Lassman C: Fulminant hepatic fail-
ure from primary hepatic lymphoma: successful treatment
with orthotopic liver transplantation and chemotherapy.
Transplantation 2005, 80(7):993-996.
14. Hanau C, Munoz SJ, Rubin R: Histopathological heterogeneity in
fulminant hepatic failure.  Hepatology 1995, 21:345-351.
15. Page RD, Romaquera JD, Osborne B: Primary Hepatic Lym-
phoma: Favorable outcome after combination chemother-
apy.  Cancer 2001, 92(8):2023-2029.